Man Group plc Grows Position in DENTSPLY SIRONA Inc. (NASDAQ:XRAY)

Man Group plc grew its position in DENTSPLY SIRONA Inc. (NASDAQ:XRAY) by 375.1% during the 4th quarter, HoldingsChannel.com reports. The firm owned 177,962 shares of the medical instruments supplier’s stock after acquiring an additional 140,503 shares during the quarter. Man Group plc’s holdings in DENTSPLY SIRONA were worth $3,378,000 at the end of the most recent quarter.

Other institutional investors have also modified their holdings of the company. Vanguard Group Inc. lifted its position in DENTSPLY SIRONA by 0.3% during the fourth quarter. Vanguard Group Inc. now owns 20,183,260 shares of the medical instruments supplier’s stock valued at $383,078,000 after buying an additional 65,478 shares in the last quarter. First Eagle Investment Management LLC lifted its holdings in shares of DENTSPLY SIRONA by 2.5% during the 4th quarter. First Eagle Investment Management LLC now owns 14,500,409 shares of the medical instruments supplier’s stock valued at $275,218,000 after acquiring an additional 348,532 shares in the last quarter. Nuance Investments LLC lifted its holdings in shares of DENTSPLY SIRONA by 25.0% during the 4th quarter. Nuance Investments LLC now owns 13,545,981 shares of the medical instruments supplier’s stock valued at $257,103,000 after acquiring an additional 2,708,097 shares in the last quarter. Price T Rowe Associates Inc. MD boosted its position in DENTSPLY SIRONA by 18.7% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 12,549,242 shares of the medical instruments supplier’s stock worth $238,186,000 after purchasing an additional 1,975,404 shares during the period. Finally, Fuller & Thaler Asset Management Inc. increased its holdings in DENTSPLY SIRONA by 2.8% in the 4th quarter. Fuller & Thaler Asset Management Inc. now owns 11,539,418 shares of the medical instruments supplier’s stock valued at $219,018,000 after purchasing an additional 314,343 shares in the last quarter. Hedge funds and other institutional investors own 95.70% of the company’s stock.

DENTSPLY SIRONA Price Performance

XRAY opened at $15.83 on Thursday. The company has a 50-day moving average of $14.47 and a 200-day moving average of $17.24. The company has a market capitalization of $3.15 billion, a P/E ratio of -7.65, a PEG ratio of 1.80 and a beta of 0.92. DENTSPLY SIRONA Inc. has a 1-year low of $12.16 and a 1-year high of $28.44. The company has a debt-to-equity ratio of 0.72, a quick ratio of 0.84 and a current ratio of 1.25.

DENTSPLY SIRONA (NASDAQ:XRAY) last posted its quarterly earnings results on Thursday, May 8th. The medical instruments supplier reported $0.43 EPS for the quarter, topping analysts’ consensus estimates of $0.29 by $0.14. The business had revenue of $879.00 million during the quarter, compared to the consensus estimate of $854.75 million. DENTSPLY SIRONA had a positive return on equity of 12.62% and a negative net margin of 10.59%. The company’s revenue for the quarter was down 7.8% compared to the same quarter last year. During the same period last year, the firm earned $0.42 earnings per share. Equities analysts expect that DENTSPLY SIRONA Inc. will post 1.84 EPS for the current fiscal year.

DENTSPLY SIRONA Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Friday, April 11th. Stockholders of record on Friday, March 28th were issued a $0.16 dividend. The ex-dividend date of this dividend was Friday, March 28th. This represents a $0.64 dividend on an annualized basis and a dividend yield of 4.04%. DENTSPLY SIRONA’s dividend payout ratio (DPR) is -14.10%.

Insider Activity at DENTSPLY SIRONA

In other DENTSPLY SIRONA news, Director Gregory T. Lucier purchased 15,142 shares of the firm’s stock in a transaction dated Monday, March 3rd. The stock was acquired at an average cost of $16.51 per share, with a total value of $249,994.42. Following the acquisition, the director now owns 81,971 shares of the company’s stock, valued at approximately $1,353,341.21. This represents a 22.66% increase in their position. The purchase was disclosed in a filing with the SEC, which is accessible through this link. Corporate insiders own 0.52% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts recently commented on XRAY shares. Robert W. Baird dropped their target price on DENTSPLY SIRONA from $22.00 to $20.00 and set a “neutral” rating on the stock in a report on Friday, February 28th. Piper Sandler dropped their price objective on shares of DENTSPLY SIRONA from $20.00 to $16.00 and set a “neutral” rating on the stock in a research note on Wednesday, April 30th. Morgan Stanley downgraded shares of DENTSPLY SIRONA from an “overweight” rating to an “equal weight” rating and set a $14.00 target price for the company. in a research note on Tuesday, April 15th. Needham & Company LLC reaffirmed a “hold” rating on shares of DENTSPLY SIRONA in a research note on Thursday, March 13th. Finally, StockNews.com upgraded shares of DENTSPLY SIRONA from a “hold” rating to a “buy” rating in a report on Friday, May 9th. Eleven equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $20.36.

About DENTSPLY SIRONA

DENTSPLY SIRONA Inc manufactures and sells various dental products and technologies worldwide. It operates in four segments: Connected Technology Solutions, Essential Dental Solutions, Orthodontic and Implant Solutions, and Wellspect Healthcare. The company offers dental equipment comprising imaging equipment, motorized dental handpieces, treatment centers, other instruments, amalgamators, mixing machines, and porcelain furnaces; and dental CAD/CAM technologies to support dental restorations, such as intraoral scanners, 3-D printers, mills, other software and services, and a full-chairside economical restoration of esthetic ceramic dentistry, as well as DS Core, its cloud-based platform.